Your browser is no longer supported. Please, upgrade your browser.
Settings
PLRX [NASD]
Pliant Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own1.00% Shs Outstand35.45M Perf Week-4.77%
Market Cap1.14B Forward P/E- EPS next Y-2.92 Insider Trans-10.34% Shs Float32.25M Perf Month2.40%
Income- PEG- EPS next Q-0.71 Inst Own80.80% Short Float3.23% Perf Quarter10.56%
Sales94.40M P/S12.08 EPS this Y80.50% Inst Trans1.53% Short Ratio8.71 Perf Half Y28.56%
Book/sh8.47 P/B3.72 EPS next Y-34.60% ROA- Target Price- Perf Year-
Cash/sh8.12 P/C3.88 EPS next 5Y- ROE- 52W Range19.42 - 43.92 Perf YTD38.69%
Dividend- P/FCF- EPS past 5Y- ROI1.60% 52W High-28.26% Beta-
Dividend %- Quick Ratio27.90 Sales past 5Y- Gross Margin- 52W Low62.21% ATR4.10
Employees62 Current Ratio27.90 Sales Q/Q- Oper. Margin- RSI (14)48.20 Volatility14.60% 12.13%
OptionableNo Debt/Eq0.00 EPS Q/Q5.50% Profit Margin- Rel Volume1.48 Prev Close32.14
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume119.49K Price31.51
Recom1.70 SMA20-5.91% SMA508.18% SMA20019.92% Volume176,116 Change-1.96%
Jun-29-20Initiated Piper Sandler Overweight $50
Jun-29-20Initiated Needham Buy $40
Jun-29-20Initiated Cowen Outperform
Jun-29-20Initiated Citigroup Buy $40
Feb-18-21 08:30AM  
Feb-17-21 09:00AM  
Feb-09-21 08:52AM  
07:45AM  
Jan-12-21 08:00AM  
Jan-04-21 08:00AM  
Dec-11-20 12:54PM  
Dec-02-20 03:28AM  
Nov-19-20 08:00AM  
Nov-10-20 04:05PM  
Nov-09-20 08:00AM  
Oct-05-20 08:00AM  
Sep-24-20 08:00AM  
Sep-04-20 08:00AM  
Sep-03-20 12:28PM  
Aug-27-20 06:00AM  
Aug-11-20 04:05PM  
Jun-13-20 07:01AM  
Jun-05-20 04:05PM  
Jun-04-20 08:13AM  
Jun-03-20 03:54PM  
11:40AM  
07:35AM  
Jun-02-20 09:56PM  
03:46PM  
06:53AM  
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av6 and av1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of av1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cummings Keith LamontChief Financial OfficerMar 05Option Exercise2.0820,00041,60047,621Mar 05 08:51 PM
Coulie BernardPresident and CEOFeb 16Sale32.673,500114,352463,817Feb 17 07:00 PM
Coulie BernardPresident and CEOJan 14Sale26.383,50092,325467,317Jan 15 07:00 PM
Hull HansChief Business OfficerDec 30Option Exercise2.083,5007,280120,746Jan 04 08:00 PM
Cummings Keith LamontChief Financial OfficerDec 21Option Exercise2.084,5009,36027,621Dec 23 08:00 PM
Lefebvre EricChief Medical OfficerDec 18Sale26.5412,500331,752162,080Dec 21 08:00 PM
Coulie BernardPresident and CEODec 14Sale27.373,50095,790470,817Dec 16 08:00 PM
Cummings Keith LamontChief Financial OfficerDec 01Option Exercise3.6618,73468,53941,855Dec 02 08:00 PM
Cummings Keith LamontChief Financial OfficerDec 01Sale30.0018,734562,03524Dec 02 08:00 PM